Method for producing refolded protein using flow microreactor and protein refolding device

By using a micro-mixer in a flowing microreactor for high-speed mixing of buffer and denatured protein solutions, the problems of aggregates and misfolding in protein refolding are solved, and efficient recovery of protein activity and feasibility of industrial production are achieved.

CN112955458BActive Publication Date: 2024-11-29AJINOMOTO CO INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201980073108.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-11-05
Publication Date
2024-11-29
Estimated Expiration
2039-11-05

AI Technical Summary

Technical Problem

In the existing protein refolding technology, the aggregates or misfolded states are easily formed, and the process time to remove the denaturant is long, resulting in a low recovery rate of protein activity, and the problem of uneven local concentrations during industrial and large-scale production is difficult to solve.

Method used

The flow micro reactor adopts a micro-mixer with an inner diameter of 0.1 to 1.0 mm. The high-speed continuous mixing of buffer solution and denatured protein solution is controlled to be less than 3 milliseconds, the total flow rate is more than 5mL/min, and the pressure loss is in the range of 1kPa to 10MPa. Internally, inhibit the formation of agglomerates and improve the yield of correctly refolded proteins.

Benefits of technology

It achieves high yields to obtain active proteins, which are suitable for industrial large-scale production, avoids the formation of condensates and misfolded states, and improves the activity recovery rate of proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112955458B_ABST
    Figure CN112955458B_ABST
Patent Text Reader

Abstract

The present invention provides a method for producing a refolded protein, comprising the step of mixing a solubilized solution of an insolubilized protein or a protein that has lost its higher-order structure with a buffer in a micromixer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for producing a refolded protein and a protein refolding device using a flow micro reactor (FMR). Background Art

[0002] In most cases, proteins produced by microorganisms such as Escherichia coli are insoluble and inactive in the microorganism. Therefore, in order to make the obtained protein industrially usable, it is necessary to restore its activity, and thus it is necessary to refold it so that it has an appropriate three-dimensional structure.

[0003] When refolding, usually, an appropriate denaturant is used to make the insoluble protein solubilized, and then the denaturant is removed to the extent that the protein restores its three-dimensional structure and regains its activity. As methods for removing the denaturant, column chromatography such as gel filtration chromatography, ultrafiltration, dialysis, and combinations thereof are known. Through refolding, only proteins with a stable chemical potential structure and activity are desired, but many of them precipitate when the denaturant is removed, or a structure that is inactive even if dissolved in the aqueous phase after refolding is obtained, and a satisfactory yield of active protein is still not obtained.

[0004] As a technology for refolding proteins at an industrial level, for example, Japanese Patent Publication No. 2009-502173 (Patent Document 1) discloses the following method as a flow refolding method: after a solubilized protein solution and a dilution buffer are combined, they are fully mixed in a static mixer for refolding, thereby reducing the shear force of the stirring blades based on batch refolding and the pressure caused by heat.

[0005] U.S. Patent No. 7651848 (Patent Document 2, hereinafter referred to as "Patent No. 848") discloses a method of mixing a solubilized protein and a diluent with a static mixer, receiving the refolding solution in a tank, and stirring the refolding solution in the tank. According to the description, the mixing time at this time is 1 millisecond to 10 seconds, preferably 100 milliseconds to 1 second. In addition, a method of merging additives after mixing with a static mixer, a method of pre-filling a dilution buffer in a refolding tank that receives a mixed solution of a solubilized protein solution and a dilution buffer, and circulating the mixed solution in the refolding tank for diluting the solubilized protein solution is disclosed.

[0006] Non-patent document 1 (Process Biochemistry 35 (2000) 1119-1124) discloses a system in which, while a solubilized protein solution in a dialysis membrane tube is stirred, the solubilized protein is transported into the dialysis membrane tube by a pump, and a dilution buffer is transported to the outside of the dialysis membrane tube and continuously extracted to maintain the concentration of the solubilized substance at a low level.

[0007] Non-patent document 2 (Chemical Engineering Science 140 (2016) 153-160) discloses a continuous refolding system in which a solubilized protein solution and a dilution buffer are mixed, the liquid is passed through a static mixer, and then passed through a reaction coil to be refolded.

[0008] Prior art literature

[0009] Patent Literature

[0010] Patent Document 1: Japanese Patent Application No. 2009-502173

[0011] Patent Document 2: U.S. Patent No. 7,651,848

[0012] Non-patent literature

[0013] Non-patent document 1: Process Biochemistry 35 (2000) 1119-1124

[0014] Non-patent document 2: Chemical Engineering Science 140 (2016) 153-16 Summary of the invention

[0015] Technical problem solved by the invention

[0016] As described above, protein refolding is to restore protein function by folding a protein in a denatured state without protein function into its original structure, but such structural change can be induced by removing the denaturant or infinitely reducing the concentration of the denaturant. Figure 1The description of each state in Fig.4 of the document of Tsumoto et al. (K.Tsumoto et al., Protein Expression and Purification 28 (2003) 1-8) is added, showing the process of refolding. As shown in the figure, by refolding, the protein is changed from the denatured state (U) to the folded state (N) through the intermediate (I). However, the structure of the protein is considered to depend not only on the concentration of the denaturant, but also on the surrounding environment such as pH and temperature to a large extent, and due to uneven mixing, it is easy to form an aggregate or become a misfolded state (Y.Katoh et al., Process Biochemistry 35 (2000) 1119-1124). That is, it is possible to become an aggregate from a denatured state (U) and an intermediate (I). The time from the denatured state (U) to the folded state (N) or the aggregate is shorter, and it is considered to be very fast (millisecond level) (CM Dobson et al., J.Mol.Biol. (2000) 297, 193-210). Therefore, in order to suppress the formation of aggregates, it is considered to be very important to achieve a state in which the denaturant is removed or a state in which the denaturant concentration is reduced (that is, high-speed mixing) in a short time.

[0017] However, it takes a certain amount of time to remove the denaturant from the solubilized protein solution. For example, when the denaturant is removed by dialysis, the movement speed of the substance through the dialysis membrane is slow, so the time until the denaturant is removed is longer than the refolding time. In addition, at the industrial level, in addition to the time required for dilution, there is also the problem of localized uneven concentration. For example, a static mixer is an excellent mixing device, but in the process of first mixing the diluent with the solubilized solution of the denatured protein and then introducing it into the static mixer until the mixing process at the outlet of the static mixer, it is easy to have temporal and local unevenness.

[0018] Technical means of solving problems

[0019] As a result of in-depth research on the protein refolding method, the inventors found that by using a flow microreactor with a micromixer with an inner diameter of 0.1 to 1.0 mm, allowing a buffer and a solubilized solution of a denatured protein to flow at a given flow rate and continuously mixing them in the micromixer, the formation of aggregates can be suppressed and the yield of correctly refolded proteins can be increased. Based on this knowledge, the present invention was completed. That is, the present invention provides the following production method.

[0020] 1. A method for producing a refolded protein, comprising:

[0021] A step of mixing a solubilized solution of an insoluble protein or a protein that has lost its higher-order structure with a buffer solution in a micromixer.

[0022] 2. The manufacturing method according to item 1, wherein:

[0023] The mixing time obtained by the following formula (I) is less than 3 milliseconds (msec),

[0024] tm=0.15ε -0.45 (I)

[0025] Where tm is the mixing time, ε is the energy dissipation rate, Q is the flow rate, ΔP is the pressure loss, ρ is the density, V is the mixer volume, and ε = QΔP / ρV.

[0026] 3. The manufacturing method according to item 1 or 2, wherein:

[0027] The total flow rate of the buffer solution and the flow rate of the denatured protein solubilization solution is 5 mL / min or more.

[0028] 4. The production method according to any one of items 1 to 3, wherein:

[0029] The total flow rate of the buffer solution and the flow rate of the denatured protein solubilization solution is 600 mL / min or less.

[0030] 5. The production method according to any one of items 1 to 4, wherein:

[0031] The pressure loss before and after the micro mixer is 1 kPa to 10 MPa.

[0032] 6. The manufacturing method according to any one of items 1 to 5, wherein:

[0033] The mixing time in the micromixer is less than 1 millisecond.

[0034] 7. The manufacturing method according to any one of items 1 to 6, wherein:

[0035] The mixing step includes mixing the solubilized solution and the buffer solution in a micro mixer having an inner diameter of Y mm.

[0036] During mixing, the buffer solution at a flow rate of X1 mL / min is brought into contact with the solubilizing solution at a flow rate of X2 mL / min.

[0037] The relationship between X1 and Y is represented by the following formula (1):

[0038] The relationship between X1 and X2 is represented by the following formula (2):

[0039] [Mathematical formula 1]

[0040]

[0041] Where, 10≤X1,

[0042]

[0043] 8. The production method according to any one of items 1 to 7, wherein

[0044] The flow rate X1 of the buffer solution is 10 to 1500 mL / min.

[0045] 9. The method according to any one of items 1 to 8, wherein:

[0046] The inner diameter Y of the micro mixer is 0.1 to 1.0 mm.

[0047] 10. The production method according to any one of items 1 to 9, wherein:

[0048] The solubilizing solution comprises:

[0049] Urea,

[0050] Guanidine hydrochloride,

[0051] or any combination of trifluoroacetic acid and acetonitrile.

[0052] 11. The production method according to any one of items 1 to 10, wherein in the refolding method, the flow path is filled with a solution containing no protein but a denaturing agent before the solubilization solution is allowed to flow.

[0053] 12. The manufacturing method according to any one of items 1 to 11, wherein:

[0054] The refolded protein is a monomer.

[0055] 13. The manufacturing method according to any one of items 1 to 12, wherein:

[0056] The refolding step is followed by a purification step.

[0057] Furthermore, the inventors of the present invention have conducted intensive research on a protein refolding device and have found that by using a flow microreactor equipped with a micromixer having an inner diameter of 0.1 to 1.0 mm, a buffer solution and a solubilized solution of a denatured protein are continuously mixed in the micromixer, thereby suppressing the formation of aggregates and obtaining a reliably refolded protein, and have completed the present invention. That is, the present invention provides the following device.

[0058] 14. A protein refolding device, which is a device for refolding proteins, wherein the device comprises:

[0059] A first flow path for the flow of a buffer solution;

[0060] A second flow path for flowing a solubilized solution of insolubilized proteins or proteins that have lost their higher-order structures; and

[0061] The micro mixer for mixing has an inner diameter of 0.1 to 1.0 mm, and the first flow path and the second flow path merge in the micro mixer.

[0062] 15. The device according to item 14 above, which is equipped with a syringe pump, a plunger pump or a diaphragm pump, which is used to transport the buffer solution and the protein solubilization solution.

[0063] Effects of the Invention

[0064] According to the present invention, since the refolding conditions (particularly, the flow rate and mixing time of the buffer and the denatured protein solubilizing solution) can be accurately controlled, the refolded and reactivated protein can be obtained at a high yield. By using the apparatus of the present invention, when increasing the production volume, only the same system needs to be added, so that the scale can be expanded without being affected by the scale expansion. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] [ Figure 1 ] Figure 1 This is a diagram with the explanation of each state added to Fig. 4 (schematic diagram showing the refolding process) of K. Tsumoto et al., Protein Expression and Purification 28 (2003) 1-8.

[0066] [ Figure 2A ] Figure 2A It is a cross-sectional view of a T-shaped micro mixer.

[0067] [ Figure 2B ] Figure 2B This is a cross-sectional view of a V-shaped micro mixer.

[0068] [ Figure 3 ] Figure 3 This is a schematic diagram of an FMR device used in the examples.

[0069] [ Figure 4 ] Figure 4 This is a schematic diagram of an FMR device used in the examples.

[0070] [ Figure 5 ] Figure 5 This is a graph showing the relationship between the flow rate at various flow channel inner diameters and the rfIL-6 monomer yield measured in Example 1.

[0071] [ Fig. 6A ] Fig. 6A The peaks of rhIL-6 (monomer) and rhIL-6 aggregates (dimer) measured in Example 2 and refolded according to the present invention are shown.

[0072] [ Figure 6B ] Figure 6B The peaks of refolded rhIL-6 (monomer) and rhIL-6 dimer measured in Example 2 when mixing was performed in a batch manner are shown.

[0073] [ Figure 6C ] Figure 6C The peaks of refolded rhIL-6 (monomer) and rhIL-6 dimer measured in Example 2 when mixed by buffer exchange using a gel filtration column are shown.

[0074] [ Figure 7 ] Figure 7 The graph shows the lysozyme activity at various flow rates measured in Example 4.

[0075] [ Figure 8 ] Figure 8 A comparison of the mixing times of the '848 patent process and the process of the present invention, as determined in Example 6, is presented as mixing time relative to pressure loss.

[0076] [ Fig. 9 ] Fig. 9 A comparison of the mixing performance of the method of the '848 patent and the method of the present invention, measured in Example 7, is presented by absorbance at 352 nm relative to flow rate.

[0077] [ Fig.10 ] Fig.10 The graph shows the rhIL-6 monomer yields at various flow rates measured in Example 8, the method of Patent No. 848, the method of the present invention, and the batch method.

[0078] [ Fig.11 ] Fig.11 The figure shows a comparison between the total yield of IGF-1 (Ib) and precursor (Ic) refolded by the method of the present invention or batchwise and the yield of IGF-1 (Ia) measured in Example 11.

[0079] [ Fig.12 ] Fig.12 The comparison of the yields of ranibizumab refolded by the method of the present invention or by the batch method measured in Example 12 is shown. DETAILED DESCRIPTION

[0080] 1. Method of the present invention

[0081] Generally speaking, a microreactor is a reaction device that performs reactions in a space of tens to hundreds of micrometers. The microreactor used in the method of the present invention is a continuous flow type.

[0082] On the other hand, insoluble proteins or proteins that have lost their higher-order structures are solubilized by denaturants, and then, when the denaturants are removed to the extent that the solubilized proteins recover their three-dimensional structures, the proteins are refolded.

[0083] The method of the present invention uses a micro mixer provided in the FMR to continuously and rapidly mix and dilute a solubilized solution of an insoluble protein or a protein that has lost its higher-order structure with a buffer at high speed, thereby removing the denaturant from around the solubilized protein and refolding the protein.

[0084] According to the method of the present invention, high-speed mixing can be achieved in which the mixing time obtained by the following formula (I) is less than 3 msec.

[0085] tm=0.15ε -0.45 (I)

[0086] In the formula, ε is the energy dissipation rate, Q is the flow rate, ΔP is the pressure loss, ρ is the density, V is the mixer volume, ε = QΔP / ρV.

[0087] The faster the mixing time, the more the formation of aggregates can be suppressed, and the refolded protein as the target product can be obtained at a high yield. The mixing time is preferably less than 3 msec, more preferably 1.4 to 0.001 msec, further preferably 1 to 0.001 msec, and further preferably 0.87 to 0.0.001 msec.

[0088] 〔protein〕

[0089] The protein to be refolded according to the present invention is a protein that is insoluble or has lost its higher-order structure, and has lost its function or activity. In this specification, such a protein is also referred to as a denatured protein. It is not possible to clearly distinguish between an insoluble protein and a protein that has lost its higher-order structure, but they are both different from proteins whose higher-order structures are in a native state.

[0090] Insoluble proteins include, for example, genetically recombinant proteins produced using microorganisms such as Escherichia coli as production hosts. The solubility of the protein obtained in this way is usually 0.001 g or less in 100 g of water (25° C.), so it can be used in the present invention. It can also be a protein that becomes insoluble from a soluble state due to some pressure.

[0091] The form of the protein is not particularly limited, and may be, for example, granular, powdery, fibrous, or aggregated. There are also proteins that are soluble without the aid of a denaturant, even if their higher-order structures are different from those of proteins in their native state, such as aggregates. Such proteins are also the subject of refolding according to the present invention.

[0092] The present invention can be applied to proteins whose secondary structure mainly includes α-helix (e.g. IL-6), proteins containing β-fold (e.g. scFv, Fab) or proteins containing both (e.g. transglutaminase). It can also be applied to proteins with complex structures, and the characteristics of the primary structure and secondary structure of the protein are not particularly limited.

[0093] In addition, the present invention can be applied to monomeric proteins (IL-6, etc.) and also to multimeric proteins (Fab, etc.). However, since the optimal states in the refolding of multimeric and monomeric proteins are different, a higher monomer yield is obtained when adjusting to the optimal conditions of monomeric proteins compared to when adjusting to the optimal conditions of multimeric proteins. Protein fragments can also be used. For example, a fragment with a weight average molecular weight (measured by ultracentrifugation analysis, static light scattering analysis, at room temperature) of 5000 to 150000 Daltons can be used in the present invention.

[0094] The method can be applied to proteins that do not have disulfide bonds within or between molecules (e.g., transglutaminase) or proteins that have such bonds (e.g., IL-6, scFv, and Fab).

[0095] Specifically, they include: cytokines such as human interleukin-6 and IGF; protein ligands such as growth factors, various hormones (e.g., Activin A, TGF-β), and differentiation-inducing factors that function by acquiring specific higher-order structures; enzymes such as transglutaminase and lysozyme; protein enzyme inhibitors; and antibody-related molecules having an immunoglobulin structure.

[0096] Examples of antibody-related molecules include antibody fragments such as an antibody variable region (Fv), a single-chain antibody variable region (scFv), an antigen binding site (Fab), an antigen binding site (Fab'), and a bivalent antigen binding site (F(ab')2); an antibody fragment such as a single-chain antibody variable region (bispecific single chain Fv) or a diabody showing bispecificity, and an artificial minibody (Minibody) obtained by fusing an antibody variable region and a part of an antibody Fc domain into a dimer; a single-domain antibody (single-do main antibody) comprising a single domain derived from a light chain or a heavy chain in a domain constituting an antigen binding site or an antibody variable region, and an Fc fusion protein (Fc Fusion Protein) obtained by fusing a protein or a peptide to an antibody Fc domain.

[0097] More specifically, the molecules include single-chain antibody variable regions (scFv) such as HyHEL-10 scFv, such as Pexelizumab (scFv), abciximab (trade name, ReoPro), ranibizumab (trade name, LUCENTIS) or certolizumab (trade name, Cimzia) as antigen-binding sites (Fab), Fc fusion proteins (Fc fusion proteins) such as anti-Fluorescein scFv Fc fusion, such as romiplostim (trade name, Nplate), rilonacept (trade name, ARCALYST), abatacept (trade name, ORENCIA) or alefacept (trade name, AMEVIVE), which are insoluble or lose their higher-order structures. The structures of these antibody-related molecules are described in detail in known papers such as Holliger P. and Hudson PJ. Nature Biotechnology 23 (9), 1126-1136 (2005).

[0098] Artificial affinity molecules prepared using structures other than immunoglobulin structures, such as ankyrin repeats, fibronectin type III domains, lipoproteins, etc., as basic structures can also be used in the present invention.

[0099] In the present invention, the insoluble protein or the protein having lost its higher order structure is contained in a solution containing a denaturant, and after being solubilized, it is circulated in a micro mixer. The concentration of the protein in the solubilized solution is preferably set to 0.1 to 20 mg / mL, more preferably 0.25 to 5 mg / mL, and further preferably 0.5 to 3.5 mg / mL. Thus, the solubilized solution can be circulated in a micro mixer with a given inner diameter and quickly and fully mixed with a buffer solution.

[0100] 〔Denaturing agent〕

[0101] Generally speaking, denaturants are used to make proteins lose their higher-order structure and inactivate them, but in refolding, the effect of making proteins solubilized is achieved by stretching insoluble or higher-order structure-losing proteins, loosening their structure or untangling them.

[0102] In the present invention, as a denaturant that can be used to solubilize denatured proteins, any denaturant known in the art can be used without particular limitation. For example, acids such as urea, guanidine hydrochloride, trifluoroacetic acid (TFA), solvents such as acetonitrile, and surfactants can be used. Examples of surfactants include: 16 , decanoyl sarcosine (lauroyl sarcosine, lauroyl-Sar), decanoyl alanine (lauroyl alanine, lauroyl-Ala), capric acid or salts thereof (e.g., sodium salt, potassium salt), lauryl trimethyl ammonium chloride (LTAC) and mixtures thereof. 16 The acyl dicarboxylic acid, decanoyl sarcosine, decanoyl alanine or their salts are preferred. 16 More preferred is a dicarboxylic acid or a salt thereof having an acyl group of C8 to C 16 The acyl dicarboxylic acid is more preferably lauroyl glutamic acid (lauroyl-Glu), lauroyl aspartic acid (lauroyl-Asp) or lauroyl iminodiacetic acid. Lauroyl-Glu, lauroyl-Asp, lauroyl-Sar, lauroyl-Ala can be any one of D-type, L-type, DL-type. As a surfactant, lauroyl-L-Glu or its salt is excellent in solubilization ability to all insoluble proteins, can be easily removed when diluted without continuing to bind to protein, and highly purified lauroyl-L-Glu reagent can be purchased at a relatively low price, so it is particularly preferred. As the denaturant used in the present invention, due to the excellent denaturation effect, a combination of urea, guanidine hydrochloride or TFA and acetonitrile is preferred.

[0103] As for the concentration of the denaturant, any concentration that can fully stretch the denatured protein in the solution is sufficient. When the concentration of the denatured protein is as described above, it is preferably set to 4 M or more. Thus, the solubilization efficiency can be fully improved. Due to the excellent denaturation effect, it is more preferably 5 M or more, and further preferably 6 M or more. The upper limit can be set to a range that appropriately maintains the dilution ratio, preferably 10 M. When it is set to 6 to 8 M, the solubilization efficiency and the dilution ratio can be optimized.

[0104] The solvent of the solubilization solution depends on the type of denaturant used, but water is preferred. When a solvent such as acetonitrile is used as the denaturant, other solvents may or may not be used. A reducing agent such as dithiothreitol (DTT) or 2-mercaptoethanol may be added to the solubilization solution.

[0105] The pH of the solubilized solution at 25°C can be selected to be a moderate condition of pH 2.0 to 9.0, preferably pH 7.0 to 8.5, in accordance with the properties of the denatured protein. It should be noted that in the present invention, the pH can be measured by a pH meter equipped with a pH electrode. The pH adjustment can be performed using a base such as sodium hydroxide. A buffer solution can be used as the aqueous solution.

[0106] The temperature of the solubilization solution can be appropriately determined in consideration of the thermal properties of the protein to which the method of the present invention is applied, but is preferably set to about 4 to 40°C. Within such a range, modifications such as cleavage and oxidation caused by chemical reactions are suppressed to a minimum, which is preferred. The temperature of the solubilization solution can be adjusted by equipping the reservoir tank with a heat incubator, installing a pre-temperature adjustment coil outside the flow path, or immersing a micro mixer or the like in a water bath.

[0107] Whether the protein is solubilized can be confirmed by, for example, turbidity determination by naked eye observation or ultraviolet absorption spectroscopy at 280 nm.

[0108] 〔Buffer〕

[0109] The buffer that can be used in the present invention may be those known in the art, for example, Tris buffer (trihydrochloride, triacetate, etc.), phosphate buffer (PBS), sodium acetate buffer, sodium citrate buffer, etc.

[0110] The buffer may contain amino acids such as arginine, cysteine, and cystine, and additives such as oxidized glutathione and reduced glutathione. The amino acid may form a salt formed with an inorganic acid such as hydrochloride or a salt formed with an organic acid such as acetate. The amino acid may be an acylated arginine, such as a derivative of N-butyrylarginine. The concentration of the additive is selected according to the properties of the protein. In the case of arginine, for example, it is 0.1 to 1.5 M, preferably 0.2 to 1.2 M; in the case of cysteine, for example, it is 1 to 10 mM, preferably 3 to 6 mM; in the case of cystine, for example, it is 0.1 to 1 mM, preferably 0.6 to 1 mM; in the case of reduced glutathione, for example, it is 1 to 10 mM, preferably 3 to 6 mM; in the case of oxidized glutathione, for example, it is 0.1 to 1 mM, preferably 0.6 to 1 mM. Inclusion of the above concentrations can promote the restoration of the higher-order structure of the native state, so it is preferred.

[0111] The pH of the buffer at 25°C may be a pH suitable for the properties of the protein after the solubilization solution merges, and may be in the range of pH 4.0 to 9.0. The pH may be the same as or different from that of the solubilization solution. The pH adjustment may be performed, for example, with hydrochloric acid, sodium hydroxide, or the like.

[0112] The temperature of the buffer solution may be the same as or different from the temperature of the solubilizing solution, but is preferably the same. When the temperature of the buffer solution is the same as the temperature of the solubilizing solution, the refolding temperature is excellently controlled. When the thermal stability of the target protein is not high enough when it regains activity, it is preferably 4 to 10°C. The temperature of the buffer solution can be adjusted by equipping the reservoir tank with a heat incubator, installing a pre-temperature-adjusting coil outside the flow path, or immersing a micro mixer in a water bath.

[0113] The buffer solution and the solubilized solution of the denatured protein prepared as described above are supplied from different flow paths. The buffer solution and the solubilized solution of the denatured protein can be circulated by a liquid delivery pump. The flow rate of each solution can be adjusted by the pressure of the liquid delivery pump.

[0114] When the sum of the flow rate of the buffer and the flow rate of the solubilized solution of the denatured protein (hereinafter referred to as "total flow rate" or TFR) is 5 mL / min or more, the recovery rate of the reactivated protein is excellent, so it is preferred. When the TFR is 1650 mL / min or less, the selection range of the pump that can be used is expanded, so it is preferred, and more preferably 600 ml / min or less. TFR is more preferably 11 to 600 mL / min, more preferably 11 to 330 mL / min, and even more preferably 20 to 330 mL / min.

[0115] The flow path for each solution to flow may be one or more than two. When two solutions are mixed in the micro mixer, the volumes of the two solutions are preferably adjusted so that the dilution ratio is several to several dozen times, for example, 10 to 20 times.

[0116] Before the solubilization solution is circulated, the flow path may be filled with a solution containing no denatured protein but a denaturant, thereby increasing the yield of the target protein and enabling stable and continuous liquid feeding.

[0117] The two solutions that have reached the micro mixer are mixed in the micro mixer. The micro mixer used in the present invention has a small inner diameter of the flow path (therefore, sometimes referred to as a micro flow path) and is not equipped with stirring blades, barrier plates, and the like.

[0118] The inner diameter Y mm of the microchannel constituting the micromixer can be determined based on the relationship with the flow rate X1 mL / min of the buffer solution. Specifically, the relationship between X1 and Y can be expressed by the following formula (1).

[0119] [Mathematical formula 2]

[0120]

[0121] In order to achieve a satisfactory refolding rate, for example, 10≤X1. The flow rate depends on the mixing time, and is therefore preferably 10≤X1≤1500, more preferably 10≤X1≤300, and further preferably 20≤X1≤300.

[0122] When the inner diameter Y of the microchannel of the micro mixer is less than 0.1 mm, the pressure loss increases, making it difficult to use. Therefore, 0.1≤Y is preferred, 0.1≤Y≤1.0 is more preferred, 0.1≤Y≤0.5 is further preferred, and 0.25≤Y≤0.5 is particularly preferred.

[0123] More preferably, 10≤X1≤1500 and 0.1≤Y≤1.0, further preferably 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5. When X1 and Y are within such ranges, pressure loss and mixing time can be controlled, which is preferred.

[0124] More preferably, 10≤X1≤545 and 0.1≤Y≤1.0, further preferably 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5. When X1 and Y are within such ranges, pressure loss and mixing time can be controlled, which is preferred.

[0125] Particularly preferably, 10≤X1≤300 and 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5. When X1 and Y are within such ranges, mixing time and pressure loss can be controlled, which is preferred.

[0126] Most preferably, 20≤X1≤300, and 0.25≤Y≤0.5. When X1 and Y are within such ranges, stable mixing performance can be obtained, which is preferred.

[0127] The flow rate of the solubilization solution can be determined by the relationship with the flow rate of the buffer solution. That is, the relationship between X1 and X2 is as shown in the following formula (2).

[0128] [Mathematical formula 3]

[0129]

[0130] Refolding can be induced by removing the denaturant or infinitely reducing the concentration of the denaturant, so X2 is preferably less than one tenth of X1. X2 is more preferably more than one fiftieth of X1, further preferably more than one thirtieth, particularly preferably more than one twentieth, and further particularly preferably less than one tenth. The timing of starting to supply the buffer solution and the solubilizing solution may be simultaneous or different. In different cases, the solubilizing solution is supplied first.

[0131] The shape of the microchannel cross section of the micro mixer is not particularly limited, and a V-shape, a T-shape, etc. can be used. Since higher mixing performance can be expected, a V-shape is preferred.

[0132] Since higher mixing performance can be obtained, the microchannel cross-section of the micromixer is more preferably V-shaped, 10≤X1≤1500, and 0.1≤Y≤1.0, further preferably 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5.

[0133] Since higher mixing performance can be obtained, the microchannel cross-section of the micromixer is more preferably V-shaped, 10≤X1≤545, and 0.1≤Y≤1.0, further preferably 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5.

[0134] Since higher mixing performance can be obtained, the microchannel cross-section of the micromixer is particularly preferably V-shaped, 10≤X1≤300, and 0.1≤Y≤0.5, and particularly preferably 0.25≤Y≤0.5.

[0135] Since higher mixing performance can be obtained, it is most preferable that the shape of the cross section of the fine flow path of the micro mixer is V-shaped, 20≤X1≤300, and 0.25≤Y≤0.5.

[0136] The pressure loss before and after the micro mixer is preferably 1 kPa to 10 MPa. By setting the pressure loss within this range, the mixing efficiency of the micro mixer can be improved, and scale-up in the manufacturing process can be easily implemented. The pressure loss can be controlled mainly by setting the specific gravity, flow rate and pressure of the buffer solution and the solubilized solution.

[0137] In the present invention, the refolding yield is improved by mixing for at most 1 millisecond. The mixing time can vary according to the flow rate, density, volume of the micro mixer, etc. of the two solutions, for example, it can be 10 microseconds to 1000 microseconds, especially 10 microseconds to 500 microseconds. Such mixing in a short time is also to quickly dilute the solubilized solution of the denatured protein and quickly remove the denaturant. Since a uniform solvent phase is obtained by rapid dilution, the structure of the intermediate also becomes homogeneous. On the other hand, when the dilution is slow, the diluted solvent phase becomes uneven, and in addition to the intermediate, there are proteins that remain stretched due to the denaturant, and the structure of the obtained protein is also various. When the intermediate is stuck in the stretched protein, the structure formation will end in the associated state. Although not bound by any theory, as mentioned above, the inventors believe that high-speed mixing helps to inhibit the formation of coacervates.

[0138] The mixing time can be quantified from the pressure loss and estimated by the following method.

[0139] (Calculation method)

[0140] In the report of Falk et al. (Chemical Engineering and Processing 50 (2011) 979-990), it was shown that the mixing time tm is related to the energy dissipation rate ε. The mixing time is expressed as follows:

[0141] tm=0.15ε -0.45 (I)

[0142] (ε=QΔP / ρV, Q: flow rate, ΔP: pressure loss, ρ: density, V: mixer volume).

[0143] The temperature after the two solutions are mixed is the same as that of the solubilized solution of the denatured protein, preferably 4 to 40°C. If the thermal stability of the target protein is not high enough when it regains activity, it can be 4 to 10°C. If it is within this range, the modification such as cutting and oxidation caused by chemical reactions can be suppressed to a minimum. The temperature after the two solutions are mixed can be adjusted by a thermostatic bath such as a water bath set in a micro mixer.

[0144] By diluting in the micro mixer, the denatured protein restores its higher order structure and regains activity. The reactivated protein is sent to the retention tube together with the solubilized solution and buffer solution that originally contained it. The flow rate at this time is not particularly limited, but in order to obtain sufficient mixing performance, it is preferably 10 to 1500 mL / min.

[0145] After the mixture is discharged from the micro mixer, the flow path can be replaced with a buffer, thereby suppressing the aggregation of proteins in the flow path.

[0146] The solution transferred from the micromixer to the retentate tube may contain incompletely refolded intermediates (i.e., Figure 1 I), but by retaining the solution in the retention tube, the denatured protein restores its higher-order structure and regains activity. That is, the refolding rate after passing through the retention tube is improved compared to just after passing through the micro mixer. The solution in the retention tube can be left or allowed to stand, or it can be circulated or stirred. The retention time is several hours to several days, for example, 2 hours to 24 hours. The retention temperature is preferably about 4 to 40°C. As described later, a container such as a beaker can be used instead of the retention tube.

[0147] The solution containing the refolded protein after passing through the retention tube is taken out from the outlet and, if necessary, placed in a receiving container.

[0148] The protein placed in the receiving container can be purified by a common method, such as ultrafiltration, dialysis, ion exchange chromatography, gel filtration chromatography, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography, and the like.

[0149] The target protein can be recovered by separation based on the above chromatography.

[0150] Whether the protein has restored its native higher-order structure can be confirmed by spectroscopic measurements such as CD spectroscopy and fluorescence spectroscopy, or by methods for observing the physicochemical properties of the protein such as HPLC, or by higher-order structural indicators such as enzyme activity.

[0151] 2. Device of the present invention

[0152] As described above, the method of the present invention can be continuously performed using a microreactor equipped with a micro mixer. Therefore, the present invention also provides: a protein refolding device that can use the method of the present invention. The device of the present invention is described below.

[0153] Generally speaking, a microreactor is a reaction device that performs reactions in a space of tens to hundreds of microns, and can achieve high-speed mixing. The device of the present invention comprises: a first flow path for the flow of a buffer solution; a second flow path for the flow of a solubilized solution of an insoluble protein or a protein that has lost its higher-order structure; and a micro mixer, in which the buffer solution and the solubilized solution merge. The first flow path and the second flow path are in communication with the micro mixer. The device of the present invention is also a continuous flow type.

[0154] The micro mixer used in the present invention can use the usual micro mixers such as slit type, disc type, and forced contact type. The slit type micro mixer is a mixer that forms multiple fine flow paths by bending the rectangular partition wall with waves parallel to the short side in a form parallel to the short side in a screen-like manner at equal intervals. The disc type micro mixer is a mixer that forms a fine flow path by stacking thin foils. The forced contact type micro mixer is a mixer based on a nozzle. Any micro mixer can make the contact (i.e., confluence) and mixing of buffer and solubilized solution simultaneously, so it is not necessary to use other mixers such as static mixers to further mix the mixed solution that has passed through the micro mixer. That is, by the present invention, the confluence and mixing of two solutions can be carried out in one step. Since it is possible to obtain excellent mixing performance while minimizing the clogging problem caused by the flow path, it is preferred to force contact type.

[0155] As described with reference to FIG. 2 , the forced contact type micro mixer increases the contact area of ​​the fluid by forcibly causing convection in the micro space, thereby promoting molecular diffusion and rapidly mixing. Among them, the simplest type of micro mixer that causes fluid collision is Figure 2A The T-shaped micro mixer and Figure 2B A V-shaped micro mixer is represented. In each case, the forced contact type micro mixer is connected to the first flow path and the second flow path, and a buffer solution (in the figure, "solution 1") and a solubilized solution of denatured protein (in the figure, "solution 2") flow into each flow path. When the individual fluids collide, convection occurs due to the kinetic energy of the fluids, thereby promoting mixing, and the mixed solution is discharged from the third flow path. The diffusion time of the liquid in the micro mixer is proportional to the kinetic energy of the fluid and the width of the flow path. Therefore, when the flow rate is 5 mL / min or more and the inner diameter Y is 0.1 to 1.0 mm, high-speed mixing and precision mixing can be efficiently performed, so a micro mixer with such an inner diameter Y is more preferred. It is further preferred that the flow rate is 11 mL / min or more and the inner diameter Y is 0.1 to 0.5 mm. It is particularly preferred that the flow rate is 22 mL / min or more and the inner diameter Y is 0.25 to 0.5 mm. The length of the micro flow path through which solution 1 and solution 2 pass respectively ( Figure 2A and Figure 2BIn the embodiment of the present invention, L1 and L2 are preferably set to 10 to 20,000 μm, more preferably to 100 to 5,000 μm, and preferably to 200 to 3,000 μm because sufficient mixing performance can be obtained. It should be noted that L1 and L2 may be the same or different from each other, but are preferably the same. The material constituting the micro mixer may be any of metal, glass, and silicon. The micro mixer may be purchased from, for example, Fraunhofer IMM, YMC, or Sanko Seiki Kogyo.

[0156] In the micro mixer, the buffer and the solubilized solution of the denatured protein are brought into contact and mixed to produce a refolded protein or an intermediate thereof. The buffer and the solubilized solution of the denatured protein that can be used here are as described above. The flow paths of the buffer and the solubilized solution can be directly connected to the micro mixer, so that the buffer and the solubilized solution merge in the micro mixer and are mixed.

[0157] Although not bound by any theory, the present inventors speculate that even if the refolding in the micromixer is not completed, since the intermediate obtained in the micromixer according to the present invention has the structure required for the correct refolding, the active structure (i.e., Figure 1 When indicated in the figure, the reaction proceeds from I to N).

[0158] The device of the present invention may be equipped with a storage tank for storing each solution before circulation. The storage tank may be equipped with a heating and heat preservation function.

[0159] Except that both ends are open, the first flow path and the second flow path constitute a closed space. The inner diameter of the first flow path and the second flow path is preferably, for example, 2 mm. As the material of the flow path, inorganic materials such as SUS and organic materials such as polytetrafluoroethylene (PTFE) can be used. The length of the first flow path and the second flow path is, for example, 0.1 to 5.0 m. Thus, temperature control can be performed.

[0160] The micro mixer can be connected to a third flow path through which the two liquids that merge in the micro mixer flow. The inner diameter and material of the third flow path are the same as those of the first and second flow paths. The length of the third flow path is, for example, 0.1 to 5.0 m. Thus, the temperature of the mixed solution can be controlled.

[0161] The circulation of the buffer solution and the solubilized solution of the denatured protein can be performed by a liquid feeding pump provided in the first flow path and the second flow path. As the liquid feeding pump, a syringe pump, a plunger pump or a diaphragm pump can be used. The pressure of the liquid feeding pump is set so that the flow rate of each solution is within the above range.

[0162] In order to improve the mixing efficiency in the micro mixer, the buffer solution is preferably pressurized by a pump for the buffer solution, and the solubilized solution is pressurized by a pump for the solubilized solution, thereby supplying the pressurized buffer solution and the pressurized solubilized solution to the micro mixer. In order to prevent one raw material from flowing into the supply pipe of another raw material and to prevent the backflow of the mixed solution, a back pressure valve is preferably installed at the buffer supply pipe and the solubilized solution supply pipe upstream of the micro mixer, respectively. The position of the back pressure valve is preferably set as close to the confluence point as possible.

[0163] The buffer solution and the solubilization solution are mixed in the micro mixer to perform protein refolding, and the flow rates of the two solutions flowing into the micro mixer and the inner diameter of the micro mixer are set as described above so that accurate refolding can be performed in a short time.

[0164] The mixture leaving the micromixer is transferred to a receiving tank. The protein in the receiving tank has been refolded and can be used directly or stored in the tank before use.

[0165] A retention tube can be provided between the micro mixer and the receiving tank. According to the present invention, it is presumed that the intermediate required for correct refolding is produced by mixing in the micro mixer, and the intermediate will automatically refold into an active protein if it is left untreated afterwards. Therefore, it is not necessary to retain the mixed solution in the retention tube, but in order to reliably complete the refolding and improve the refolding rate, it is preferably left for a certain period of time after mixing. That is, the retention tube is used as a position for placing the mixed solution. Therefore, the retention tube can have a longer flow path so that the mixed solution can pass for a long time. As its shape, it can be, for example, coil-shaped. In addition, the retention tube is also used to receive the mixed solution violently discharged from the micro mixer so that it does not leak. Therefore, any container such as a beaker can also be used instead of the retention tube. The mixed solution can be left standing in the container or stirred.

[0166] The device of the present invention may be provided with a coil for adjusting the temperature of the solubilized solution and / or buffer solution of the denatured protein in the first flow path and / or the second flow path. A water bath may also be used as a temperature regulating component. The temperature is adjusted by immersing the micro mixer, the first flow path and / or the second flow path connected thereto, the third flow path provided as required, the retention tube and other containers in the water bath.

[0167] The lengths of the first flow path and the second flow path are determined so that the temperature of the solubilization solution reaches a suitable temperature for refolding the protein contained in the solution before the two solutions are mixed.

[0168] The device of the present invention can also be provided with a temperature regulating element such as a pre-temperature adjustment coil, a water bath, etc. By arranging the coil between the first flow path and the second flow path and the micro mixer M1, the temperature of the two solutions can be adjusted to the desired temperature when the two solutions arrive at the micro mixer. The coil can also be arranged only in any one of the first flow path and the second flow path, but since the mixing efficiency will not be reduced when the temperature of the two solutions is the same when mixing in the micro mixer, it is preferred that both are installed. When the micro mixer is arranged in a water bath, the temperature of the solution before and after mixing can be adjusted. The water bath can include the first flow path, the second flow path and the third flow path connected to the micro mixer, and can also include a pre-temperature adjustment coil and a retention tube arranged when necessary.

[0169] Reference Figure 3 and Figure 4 Specific examples of the refolding device of the present invention will be described respectively.

[0170] Figure 3 In the embodiment, the first flow path 3 for circulating the buffer solution is immediately downstream of the storage tank 1 storing the buffer solution, and the second flow path 4 for circulating the solubilized protein is immediately downstream of the storage tank 2 storing the solubilized solution of the denatured protein, and the first flow path 3 and the second flow path 4 are directly connected to the micro mixer M1. The micro mixer M1 is also connected to the receiving tank 7 for receiving the mixed solution via the third flow path for circulating the mixed solution. The first flow path 3 and the second flow path 4 are respectively provided with pumps 5 and 6 for sending the buffer solution and the solubilized protein solution, so that the flow rates of the buffer solution and the solubilized solution when flowing into the micro mixer are within the above range.

[0171] Figure 4 is Figure 3 On the basis of the microreactor device, coils P1 and P2 for pre-temperature adjustment, a retention tube R1 and a water bath (indicated by dotted lines in the figure) are added. Coils P1 and P2 are arranged between the liquid delivery pumps 5 and 6 and the micro mixer M1, so that both solutions are adjusted to the desired temperature when they reach the micro mixer M1. The retention tube R1 is arranged between the micro mixer M1 and the receiving tank 7, so that the mixed solution flowing out of the micro mixer M1 is temporarily received, and in the presence of intermediates, the protein is changed to an active folded state, thereby completing the refolding. The coils P1 and P2 for pre-temperature adjustment, the micro mixer M1, the retention tube R1, the first flow path, the second flow path and the third flow path are arranged in a water bath for temperature adjustment, so that the temperature of the two solutions can be adjusted before and after mixing.

[0172] The device of the present invention can be used alone, but the production capacity can be increased by connecting multiple devices in series or in parallel. According to the present invention, it is easy to scale up by simply adding the same system without the scale gap being affected by the scale-up.

[0173] Example

[0174] Overview of FMR Device and Operation

[0175] Figure 3 The schematic diagram of the FMR device is shown. The FMR device is composed of the following components: storage tanks 1 and 2 (with a heat preservation function) for storing a buffer solution and a solubilized solution of a denatured protein, a first flow path 3 for circulating the buffer solution, a second flow path 4 for circulating the solubilized protein, injection pumps 5 and 6 for sending the buffer solution and the solubilized protein, a micro mixer M1, and a receiving tank 7 for receiving the mixed solution. The micro mixer M1 is Figure 2A T-shaped micro mixer or Figure 2B The V-shaped micro mixer is shown in FIG. The flow paths of the first flow path 3 and the second flow path 4 are 1.0 m. It should be noted that the device adopts a method that can be used as required. Figure 4 The structure shown in FIG. 1 uses coils P1 and P2 for pre-temperature adjustment, a retention tube R1, and a water bath for temperature adjustment (indicated by a dotted line in the figure). The inner diameter and shape of the flow path in the micro mixer M1 are shown in Table 1. It should be noted that the inner diameter of the flow path refers to the width of the flow path in the mixing section.

[0176] [Table 1]

[0177] type Flow path inner diameter Y Flow path shape <![CDATA[L1]]> <![CDATA[L2]]> 1 0.2mm V 2.5mm 2.5mm 2 0.25mm V 2.5mm 2.5mm 3 0.5mm V 2.5mm 2.5mm 4(for comparison) 1.0mm T 2.5mm 2.5mm 5 1.0mm V 2.5mm 2.5mm

[0178] In the following examples, the refolding was performed using the FMR device constructed in this way. Specifically, the buffer solution and the solubilized protein stored in the storage tank were transported by a liquid delivery pump and mixed in a micro mixer. It should be noted that when the mixing temperature is to be changed, the micro mixer is immersed in a water bath. It should be noted that, unless otherwise specified, the mixing temperature is set to 25°C.

[0179] [Preparation of solubilized solutions of insoluble proteins or proteins that have lost their higher-order structures]

[0180] As described below, a commercially available protein is denatured using a denaturing agent to prepare a solubilized solution of the insolubilized protein or the protein that has lost its higher-order structure.

[0181] Recombinant human IL-6 (rhIL-6) was dissolved in a 0.1% TFA, 40% acetonitrile solution and denatured (denatured rhIL-6 concentration 3.5 mg / mL, pH 2.0). Hereinafter, this solution is referred to as "denatured rhIL-6 solution A".

[0182] Recombinant human IL-6 (rhIL-6) was dissolved in 8M guanidine hydrochloride solution (pH 9.0) and denatured (denatured rhIL-6 concentration 3.5 mg / mL, pH 9.0). Hereinafter, this solution is referred to as "denatured rhIL-6 solution B".

[0183] Recombinant human IL-6 (rhIL-6) was dissolved in 8M urea solution and denatured (denatured rhIL-6 concentration 3.5 mg / mL, pH 9.0). Hereinafter, this solution is referred to as "denatured rhIL-6 solution C."

[0184] 8M guanidine hydrochloride and 4M DTT solution were added to a 2 mg / mL lysozyme solution to denature it (lysozyme concentration 0.5 mg / mL, pH 9.0). Hereinafter, this solution is referred to as "denatured lysozyme solution."

[0185] [Example 1] Refolding of rhIL-6 (1)

[0186] In Example 1, the effects of the flow rate of the buffer and the flow path shape of the micromixer on the yield of refolded rhIL-6 were studied.

[0187] The denatured rhIL-6 solution A prepared as above was mixed with a buffer solution (50 mM sodium acetate, pH 4.3) by an FMR device and diluted 20 times (rhIL-6 concentration 0.175 mg / mL). The obtained sample was quantified by gel filtration chromatography (Superdex 75 10 / 300GL (GE Healthcare)) which can separate the target product and by-products. 20 μL of the supernatant was subjected to gel filtration HPLC (column, Superdex 7510 / 300GL, manufactured by GE Healthcare; developing solution 0.1 M sodium phosphate, 0.2 M arginine hydrochloride, 1 M urea, pH 6.8; flow rate 0.8 mL / min; detection method, ultraviolet absorption at 225 nm and 280 nm; quantitative standard sample, purified rhIL-6) to quantify the rhIL-6 formed into monomeric structure, dimer and coacervate structure.

[0188] It should be noted that the buffer solution and the denatured rhIL-6 solution were introduced into the FMR device constructed as above at various flow rates ( Figure 3 The micro mixer is type 1 or type 3). The introduction start time of the two solutions is set to be simultaneous. The flow rate of each solution is shown in Table 2.

[0189] [Table 2]

[0190]

[0191] The results are shown in Figure 5 . Figure 5The horizontal axis "total flow rate" represents the sum of the flow rate of the buffer solution and the flow rate of the solubilized solution of the denatured protein ( Figure 7 , 9 , 10, 11, and 12 are the same). It should be noted that when refolding is performed correctly, rhIL-6 is obtained as a monomer, so Figure 5 The monomer yield is used to represent the yield of rhIL-6. Figure 5 It can be seen that when the flow rate increases, the yield also increases. Figure 5 It is also known that the yield is improved by reducing the inner diameter of the flow path in the mixer from 0.5 mm to 0.2 mm. The high-speed mixing using FMR can suppress the formation of aggregates and improve the yield.

[0192] [Example 2] Refolding of rhIL-6 (2)

[0193] In Example 2, refolding was performed using the FMR apparatus of the present invention, a batch method or a gel filtration column, and the refolding rates were compared.

[0194] The solubilization solution and buffer for denatured protein were the same as those used in Example 1.

[0195] The refolding according to the present invention was carried out in the same manner as in Example 1 except that Type 3 was used as a micro mixer, the flow rate of the buffer was set to 38 mL / min, and the flow rate of the denatured protein solution A was set to 2.0 mL / min.

[0196] In the batch method, the denatured rhIL-6 solution was added dropwise to a reactor in a beaker filled with dilution buffer and stirred with a magnetic stirrer. The scale of the solution was set to 10 mL.

[0197] The buffer exchange using the gel filtration column was performed by the method described in BIOTECHNOLOGY AND BIOEN GINEERING, VOL. 62, NO. 3, FEBRUARY 5, 1999.

[0198] The results are shown in FIG6 . Fig. 6A The peaks represent rhIL-6 (monomer) and rhIL-6 aggregates (dimer) refolded by the present invention. Figure 6B The peaks represent the refolded rhIL-6 (monomer) and rhIL-6 dimer when mixed intermittently. Figure 6C The peaks of refolded rhIL-6 (monomer) and rhIL-6 dimer when mixed by buffer exchange using a gel filtration column are shown. The results of FIG6 are summarized in Table 3.

[0199] [Table 3]

[0200] Comparison of refolding yields based on solvent and acid denaturation

[0201] condition monomer(%) Dimer FMR 93 7 Intermittent refolding 42 58 Column exchange 52 48

[0202] [Example 3] Refolding of rhIL-6 (3)

[0203] In Example 3, the refolding rate of the protein denatured by guanidine was compared between the present invention and the batch method.

[0204] The experiment was carried out in the same manner as in Example 2 except that the denatured rhIL-6 solution B was used as the denatured protein solubilization solution and 50 mM sodium acetate (pH 5.0) was used as the buffer.

[0205] Table 4 shows the yields of refolded rhIL-6 (monomer) and rhIL-6 aggregates (dimers) when denatured rhIL-6 solution B and buffer were mixed. As shown in Table 4, high-speed mixing using FMR can suppress the formation of aggregates and improve the yield compared to mixing by batch method.

[0206] [Table 4]

[0207] Comparison of refolding yields based on guanidine denaturation

[0208] condition monomer(%) Dimer FMR 91.2 8.8 Intermittent refolding 77.1 22.9

[0209] [Example 4] Refolding of lysozyme

[0210] In Example 4, the effects of the flow rate of the buffer and the flow path shape of the micromixer on the yield of the refolded lysozyme were studied.

[0211] The denatured lysozyme solution prepared as above was mixed with a buffer (6 mM Cys, 0.6 mM Cystine, 20 mM Trisacetate) and diluted 10 times. The buffer and lysozyme solution were introduced into the FMR device ( ) constructed as above with a micromixer of type 2 (V0.25), type 3 (V05), or type 4 (T1.0) at various flow rates. Figure 3 ). The flow rate of each solution is shown in Table 5. The introduction start time of the two solutions was set to be simultaneous. The pre-temperature adjustment coils P1 and P2 were used to adjust the temperature of the two solutions to 4°C.

[0212] For comparison, a batch method was used instead of the FMR device for mixing. In the batch method, a denatured lysozyme solution was added dropwise to a reactor filled with a dilution buffer in a beaker and stirred with a magnetic stirrer. The scale of the solution was set to 10 mL.

[0213] The mixed sample was allowed to stand for 2 hours, and the enzyme activity was measured using a lysozyme activity kit (LY0100-kit, Sigma). The results are shown in Figure 7 .

[0214] [Table 5]

[0215]

[0216] [Example 5]

[0217] In Example 5, conditions for stably performing continuous liquid feeding were studied.

[0218] (Experimental Method)

[0219] The denatured rhIL-6 solution B prepared as above was diluted with 20 mM TrisHCl buffer (pH 90) (20-fold dilution), and the ratio of monomer / dimer was calculated in the same manner as in Example 2. At this time, the following two conditions were compared: the condition in which the reactor was first filled with 8 M guanidine hydrochloride solution and then the buffer solution was circulated, and the condition in which the reactor was first filled with water and then the buffer solution was circulated. It should be noted that the buffer solution and the denatured rhIL-6 solution B were introduced into the FMR device of the above structure at various flow rates ( Figure 3 , the micro mixer is type 3). The introduction start time of the two solutions is set to be simultaneous. The flow rate of each solution is shown in Table 6.

[0220] [Table 6]

[0221]

[0222] (result)

[0223] Table 7 shows the comparison of the conditions of the solution in the reactor before the liquid delivery in each condition. Under the condition of being replaced by water in the reactor, the yield is generally low despite some fluctuations. This is believed to be because, although the water in the reactor dilutes the denaturant concentration inside the micro mixer and is in a state where refolding is promoted, on the other hand, since it is not a solution state suitable for refolding, the formation of aggregates is promoted. On the other hand, under the condition of being replaced by a denaturant inside the reactor, a stable refolding yield can be obtained.

[0224] [Table 7]

[0225] Comparison of yields under various conditions

[0226]

[0227] [Example 6]

[0228] In Example 6, the mixing times of a flow microreactor and a static mixer were compared.

[0229] As described in the above-cited Patent No. 848, the mixing time of the denatured protein solution and the buffer solution is about 1 msec to about 10 sec. Therefore, the mixing time was estimated by a method of quantifying the mixing time by pressure loss using a model protein.

[0230] (Calculation method)

[0231] In the report of Falk et al. (Chemical Engineering and Processing 50 (2011) 979-990), it was shown that the mixing time is related to the energy dissipation rate ε, and the mixing time tm is expressed as follows:

[0232] tm=0.15ε -0.45 (I)

[0233] (ε=QΔP / ρV, Q: flow rate, ΔP: pressure loss, ρ: density, V: mixer volume) This method was used to evaluate the mixing performance.

[0234] (condition)

[0235] <Study of Refolded Protein Production Using Model Proteins>

[0236] Liquid delivery system: continuous liquid delivery device (equipped with flow and pressure gauges)

[0237] Micro mixer: inner diameter 0.5 mm, V-shaped, mixer volume V: 1.9×10 -9 m 3 )

[0238] Flow rate Q: 100mL / min

[0239] Pressure loss ΔP: 6~7MPa

[0240] Density ρ: 1000kg / m 3

[0241] Substitute the above data into formula (I) to calculate the mixing time tm.

[0242] <Patent No. 848>

[0243] According to the embodiment of Patent No. 848, a three-way connector, a static mixer, and a silicon tube (inner diameter 5 mm×80 cm) were used. It should be noted that the patent does not specify the inner diameter of the three-way connector, so from the inner diameter of the silicon tube, it is inferred that a 1 / 4 inch (inner diameter 6.35 mm) connector was used. The pressure loss was measured based on the embodiment, and the result was about 20 kPa (=0.02 MPa).

[0244] (result)

[0245] Figure 8 A graph showing the mixing time relative to the pressure loss ΔP. ​​Under the conditions (6-7MPa) implemented in the refolding of the protein using the model protein, the mixing time is estimated to be about 0.05msec (=50μsec). In addition, it was found that the pressure loss of 1msec was 8kPa (=0.008MPa). It is therefore believed that the conditions used in the manufacture of FMR are outside the scope disclosed in Patent No. 848. On the other hand, based on the graph of Patent No. 848, it was found that the mixing performance was significantly reduced compared to FMR. The result is that the mixing time under the pressure loss of 8kPa is estimated to be 22.68msec, and the mixing performance is significantly lower. In order to obtain a mixing performance of less than 1msec, it is necessary to apply a pressure of about 15MPa.

[0246] [Example 7]

[0247] In Example 7, the mixing performance of a flow microreactor and a static mixer was compared.

[0248] In Patent No. 848, a static mixer is used for mixing. Therefore, the mixing performance of the flow microreactor and the static mixer was evaluated by using the Dushman reaction (competitive reaction using neutralization reaction and reduction reaction. Ehrfeld, W. et al.; Ind. Eng. Chem. Res. 38 1075-1082 (1999)), which is one of the methods for evaluating mixing performance.

[0249] (Reaction Principle)

[0250] The reaction rates of the neutralization reaction of boric acid and the reduction reaction of iodine are different. When the mixing speed is fast, reaction (1) proceeds, so no color is developed. On the other hand, when the mixing speed is slow, reaction (2) proceeds to produce I 3- , so the solution is yellow.

[0251]

[0252]

[0253]

[0254] (method)

[0255] Solutions 1 and 2 of the compositions shown in Table 8 were prepared, and the two solutions were mixed at a ratio of 1:1 using an FMR or a static mixer, and then the absorbance at 352 nm was measured using an absorbance meter. It should be noted that the FMR device used was the type shown in Figure 2 (the micro mixer was type 3 in Table 1).

[0256] [Table 8]

[0257]

[0258] (result)

[0259] Fig. 9 The comparison of the absorbance at 352 nm relative to the flow rate is shown. The absorbance is almost 0 under the condition of 10 mL / min or more using FMR, and although the absorbance is lower under the conditions assumed in the embodiment of the 848 patent, it is still about 0.9 even under the maximum condition of 200 mL / min of the liquid delivery device used this time.

[0260] [Example 8]

[0261] In Example 8, the monomer yields of the flow microreactor and the static mixer using rhIL-6 were compared.

[0262] In Patent No. 848, protein refolding is performed by a continuous process using a static mixer (hereinafter referred to as "CFR"). Therefore, using the refolding model of IL-6, the monomer yields of FMR and CFR were compared.

[0263] (Experimental Method)

[0264] The denatured IL-6 solution A prepared as above was mixed with a buffer solution (50 mM sodium acetate, pH 5.0) (dilution ratio 20 times). The mixing method was implemented by FMR, CFR or batch mode. The mixing conditions are shown in Table 9.

[0265] After mixing, the sample was allowed to stand for 1 hour or 24 hours, and then subjected to gel filtration chromatography to calculate the ratio of monomer / dimer. The quantification of rhIL-6 formed into monomer and dimer was carried out in the same manner as in Example 1. It should be noted that in this system, no coacervate, trimer, or tetramer was produced, and almost all of them became dimers when refolding failed, so the yield of the refolded protein was evaluated by the ratio of monomer / dimer.

[0266] [Table 9]

[0267] Mixing conditions

[0268]

[0269] (result)

[0270] The results are shown in Table 10 and Fig.10 Table 10 shows the analysis results of gel filtration chromatography. Fig.10The comparison of monomer ratios relative to flow rates is shown. In the case of the intermittent method, the monomer ratio is 48% to 68%, which is a result with large fluctuations. In contrast, in the case of FMR, the results under the conditions of 2.5 and 5.0 mL / min are less than or equal to those under the intermittent conditions. This reproduces the results of the Dushman reaction. On the other hand, under conditions of 10 mL / min or more, results greater than those of the intermittent method are shown. In contrast, even if the flow rate is increased under the conditions of CFR, the monomer ratio is less than 80%, etc., and does not exceed FMR. From the above results, it can be confirmed that FMR is a method of mixing speed that exceeds CFR.

[0271] [Table 10]

[0272] SEC; Analytical Results

[0273]

[0274] C1, C2, C6-C9: Comparative Examples

[0275] [Example 9] Refolding of Activin A

[0276] (Strain·Cultivation)

[0277] The synthetic gene encoding activin A was inserted into the E. coli BL21 strain using a commercially available pET vector to construct the strain. The strain was cultured in LB medium and then cultured in Select Soytone medium. After the culture solution was recovered, it was centrifuged to recover the bacterial cells.

[0278] (Preparation of Insoluble Granules)

[0279] The recovered bacterial cells are crushed by an ultrasonic crusher while cooling, and then centrifuged again to recover the precipitate, and washed with a buffer solution as needed.

[0280] (Refolding raw material preparation)

[0281] The insoluble particles were suspended by a denaturant and a reducing agent. The denaturant and the reducing agent were added so that the denaturant was 8M urea (Urea) and the reducing agent was 100mM DTT. After standing, centrifugation was performed to recover the supernatant, and then DTT was removed by passing through a Sephadex G-25 column.

[0282] (FMR refolding)

[0283] The denatured activin A solution prepared above was mixed with a buffer (0.75% taurodeoxycholic acid, 0.75 M urea, 10 mM EDTA, 20 mM Tris HCl, 1.5 mM cysteine, 0.1 mM cystine) using an FMR device to prepare an activin A refolding solution. Refolding was performed using a type 5 (V-type, inner diameter 1.0 mm) micromixer at a total flow rate of 50 mL / min and 200 mL / min.

[0284] (Intermittent refolding)

[0285] The denatured activin A solution prepared above was mixed with a buffer in a container to prepare an activin A refolding solution. Refolding was performed at reaction scales of 1 L and 5 L.

[0286] (Quantification of Activin A)

[0287] The sample refolded by FMR or intermittent was concentrated and then buffer exchanged. Then, activin A was quantified by reverse phase HPLC Vydac214 TP54 (developing solvent: A solution 0.1%-TFA, B solution 0.1%-TFA, 80% acetonitrile solution, detection method UV absorption at 280nm; quantitative standard sample, purified activin A).

[0288] (result)

[0289] Comparison of activin A yields in each scale is shown in Table 11. In the case of intermittent refolding, it was confirmed that the yield tended to decrease as the scale was enlarged (scale-up), while in the case of refolding using FMR, it was confirmed that the yield tended to be maintained. Thus, the superiority of refolding by FMR when scale-up can be confirmed.

[0290] [Table 11]

[0291] Reaction scale 1.0L 5.0L Intermittent 13.7% 8.7% FMR, total flow rate 50mL / min 200mL / min FMR 16.1% 15.1%

[0292] [Example 10] T3GF-β refolding

[0293] The synthetic gene encoding TGF-β3 was inserted into the E. coli BL21 strain using a commercially available pET vector to construct the strain. The strain was cultured in LB medium, the culture solution was recovered, and then centrifuged to recover the bacterial cells.

[0294] (Preparation of Insoluble Granules)

[0295] The recovered cells are cooled and crushed by ultrasonic crusher, and then centrifuged again to recover the precipitate, and washed with buffer solution as needed.

[0296] (Refolding raw material preparation)

[0297] The insoluble particles were suspended by a denaturant. A denaturant was added to make a 7.8 M urea solution.

[0298] (FMR refolding)

[0299] The denatured TGF-β3 solution prepared above was mixed with a buffer (4% CHAPS, 1.0 M ArgHCL, 0.5 M urea, 1 mM EDTA, 3 mM Cys) using an FMR device to prepare a TGF-β3 refolding solution. A type 5 (V-type, inner diameter 1.0 mm) micromixer was used to perform refolding at a total flow rate of 7.5 mL / min and 22.5 mL / min.

[0300] (Intermittent refolding)

[0301] The denatured TGF-β3 solution prepared above and the buffer solution were mixed in separate containers to prepare a T3GF-β refolding solution. The refolding was carried out at a reaction scale of 10 mL.

[0302] (Quantification of TGF-β3)

[0303] The refolded samples were subjected to two buffer replacement operations (first dilution: 20 mM Tris HCl, 0.5 M urea, 1 M NaCl, 1 mM EDTA (pH 7.5), second dilution: 20 mM Tris HCl, 0.5 M urea, 1 M NaCl, 1 mM EDTA, (pH 7.5)).

[0304] The obtained sample was subjected to gel filtration HPLC (column, Superdex 7510 / 300GL, manufactured by GE Healthcare; developing solution: 0.1 M sodium phosphate, 0.2 M arginine hydrochloride, 1 M urea, pH 6.8; flow rate: 0.8 mL / min; detection method: UV absorption at 225 nm and 280 nm; standard sample for quantification, purified TGF-β3) to quantify TGF-β3 that has formed a dimer structure.

[0305] (result)

[0306] Comparison of the TGF-β3 yields under various conditions is shown in Table 12. In the case of batch refolding, the yield was about 1.8%, while in the case of FMR refolding, it was 10.0% and 12.1%, which confirmed that the use of FMR can improve the yield. This confirmed the superiority of using FMR for refolding.

[0307] [Table 12]

[0308] Yield (%) Intermittent 10mL 1.8 FMR 7.5mL / min 10.0 FMR 22.5mL / min 12.1

[0309] [Example 11] IGF-1 refolding

[0310] It is known that the SS bond in the molecule of IGF-1 generates several states during refolding. In particular, the erroneous cross product (Ia) of the intramolecular SS bond generated as an IGF-1 swap body will not return to the native body (Ib) and is known to be an irreversible byproduct (Jamse, AM, (1993) Biochemistry 32, 5203-5213). On the other hand, the precursor (Ic) of the native body (Ib) will inevitably become the native body (Ib) over time. Therefore, it was decided to verify whether the high-speed mixing system using FMR can inhibit the formation of the erroneous cross product.

[0311] (Preparation of Denatured Samples)

[0312] IGF-1 was dissolved in 30 mM TrisHCl, 100 mM GSH, 8 M urea, pH 12 solution to prepare a denatured IGF-1 solution sample.

[0313] (FMR refolding)

[0314] The denatured IGF-1 solution prepared above was mixed with a buffer (50 mM Tris, 0.56 M Arg, 10 mM GSSG, pH 5) using an FMR device to prepare an IGF-1 refolding solution. Refolding was performed using a type 5 (V-type, inner diameter 1.0 mm) micromixer at a total flow rate of 15, 20 mL / min.

[0315] (Intermittent refolding)

[0316] The denatured IGF-1 solution prepared above was mixed with a buffer (50 mM Tris, 0.56 M Arg, 2.2 mM GSH, 2.2 mM GSSSG, pH 5) in a container to prepare an IGF-1 refolding solution. Refolding was performed in a 1 mL tube.

[0317] (Quantification of IGF-1)

[0318] After the obtained sample was allowed to stand for 3 hours, it was subjected to reverse phase HPLC (C8 column, manufactured by YMC; developing solvent: solution A 0.1%-TFA, solution B 0.1%-TFA, 80% acetonitrile solution, detection method: UV absorption at 280nm; standard sample for quantification, purified IGF-1) to quantify IGF-1 that had formed the misfolded structure and monomer structure of IGF-1.

[0319] (result)

[0320] The comparison of IGF-1 products under each condition is expressed as the ratio of the misfolded structure (Ia) to the monomer structure (Ib, Ic). In the case of the batch method, the misfolded structure (Ia) is 25%, while under the FMR refolding conditions, it is 17% and 18%, respectively, confirming that the percentage of misfolded structure is reduced compared to the batch method. As mentioned above, the precursor Ic will inevitably become the target product Ib over time. Therefore, the sum of Ib and Ic can be regarded as the final (obtainable) product. Fig.11 This is a graph comparing the total of Ib and Ic with Ia as an impurity. This indicates that FMR refolding is effective for refolding IGF-1.

[0321] [Table 13]

[0322] Area value of IGF under various conditions (Ia is irreversible, Ib is the product, and Ic is the precursor of Ib)

[0323]

[0324] [Table 14]

[0325] Ratio of each component % (Ia is a misfolded form)

[0326] Ia Ib Ic IGF-swap native unbridge 25.0 29.5 45.6 17.5 32.7 49.8 18.3 31.7 50.0

[0327] [Example 12] Refolding of Ranibizumab

[0328] (Preparation of Denatured Samples)

[0329] Ranibizumab (FAB fragment of the antibody) solution was added so that it became 5 mM DTT, and the mixture was left standing at 37°C for 60 min. Then, the denaturing solution was mixed so that it became 6.0 M GdnHCl, 7.5 mM EDTA, 75 mM Tris, and 1.25 mM DTT, and the mixture was left standing at 37°C for 15 min and then at 5°C overnight.

[0330] (FMR refolding)

[0331] The denatured ranibizumab solution prepared above was mixed with a buffer (0.5M ArgHCl, 0.22mM GSH, 0.22mM GSSG) using an FMR device to prepare a ranibizumab refolding solution. Refolding was performed using a type 5 (V-type, inner diameter 1.0mm) micromixer at a total flow rate of 10mL / min.

[0332] (Intermittent refolding)

[0333] The denatured ranibizumab solution prepared above was mixed with a buffer solution (0.5 M ArgHCl, 0.22 mM GSH, 0.22 mM GSSG) in a test tube to prepare a ranibizumab refolding solution. Refolding was performed in volumes of 1 mL and 10 mL.

[0334] (Quantification of Ranibizumab)

[0335] After concentration through an ultrafiltration filter, the obtained sample was subjected to gel filtration HPLC (column, Superdex 75 10 / 300GL, manufactured by GE Healthcare; developing solution: 0.1 M sodium phosphate, 0.2 M arginine hydrochloride, 1 M urea, pH 6.8; flow rate: 0.8 mL / min; detection method: ultraviolet absorption at 225 nm and 280 nm; standard sample for quantification, purified ranibizumab) to quantify ranibizumab.

[0336] (result)

[0337] Comparison of the ranibizumab yields under each condition is shown in Fig.12 In the case of intermittent refolding, in addition to ranibizumab, many misfolded forms were detected, with yields of 0.41 and 0.69%. In contrast, under FMR refolding conditions, the yield increased to 5.25%. This indicates that FMR refolding is effective for the refolding of ranibizumab.

[0338] [Example 13] Discussion of flow rate UP conditions

[0339] (FMR refolding)

[0340] The denatured rhIL-6 solution A prepared above was mixed with a buffer (50 mM AcONa, pH 5.0) using an FMR device to prepare an rhIL-6 refolding solution. Refolding was performed using a type 5 (V-type, inner diameter 1.0 mm) micromixer at a total flow rate of 10, 50, 100, and 300 mL / min.

[0341] (Quantification of rhIL-6)

[0342] The obtained sample was subjected to gel filtration HPLC (column, Superdex 75 10 / 300GL, manufactured by GE Healthcare; developing solution: 0.1 M sodium phosphate, 0.2 M arginine hydrochloride, 1 M urea, pH 6.8; flow rate: 0.8 mL / min; detection method: UV absorption at 225 nm and 280 nm; standard sample for quantification, purified rhIL-6) to quantify rhIL-6.

[0343] (result)

[0344] It can be seen that even under the conditions of total flow rates of 10, 50, 100, and 300 mL / min and an inner diameter of the micro mixer of 1.0 mm, the formation of aggregates can be suppressed by using high-speed mixing of FMR, thereby improving the yield.

[0345] [Table 15]

[0346]

[0347] [Example 14] Calculation of mixing time

[0348] The calculation of the mixing time of each micro mixer was performed according to the method of Example 6.

[0349] A mixing performance evaluation system including a syringe and a syringe pump, a pressure sensor, and a micro mixer (V-shaped inner diameter 1.0 mm) was constructed (based on Figure 3 ). Water was delivered to the constructed system at a flow rate of 5 to 80 mL / min, and the pressure loss generated at this time was measured. The pressure loss and the estimated value of the mixing time at each flow rate were calculated. The results are shown in Table 16. Based on the results, the mixing time was estimated to be less than 1 msec when the flow rate was 15 ml / min or more.

[0350] [Table 16]

[0351]

[0352] In addition, in order to measure the pressure loss in the high flow area, a mixing performance evaluation system including a plunger pump, a pressure sensor, and a micro mixer was constructed. Through the constructed system, the pressure loss when transporting water in the range of 100 to 600 mL / min was measured, and the mixing time was estimated. V-shaped and T-shaped mixers were used, and mixers with inner diameters of 1.0 mm, 0.5 mm, and 0.25 mm were used. The comparison of pressure loss and mixing time is shown in the following Tables 17 and 18. As the pressure loss depending on the flow rate increases, the estimated mixing time shows a decreasing trend. It was also confirmed that the smaller the inner diameter, the more the mixing time tends to increase.

[0353] [Table 17]

[0354] Pressure loss(Mpa)

[0355]

[0356] [Table 18]

[0357] Mixing time (msec)

[0358]

Claims

1. A method for producing a refolded protein, in, The method comprises: A step of mixing a solubilized solution of an insoluble protein or a protein that has lost its higher order structure, obtained by solubilizing an insoluble protein or a protein that has lost its higher order structure, with a buffer in a micro mixer for less than 1 millisecond to obtain a refolded protein, The denaturant is selected from urea, guanidine hydrochloride, trifluoroacetic acid, acetonitrile and a surfactant, The mixing step includes mixing the solubilized solution and the buffer solution in a micro mixer having an inner diameter of Y mm. During mixing, the buffer solution at a flow rate of X1 mL / min is brought into contact with the solubilizing solution at a flow rate of X2 mL / min. The relationship between X1 and Y is represented by the following formula (1): The relationship between X1 and X2 is represented by the following formula (2): [Mathematical formula 1] Where, 10≤X1, 2. The manufacturing method according to claim 1, in, The mixing time obtained by the following formula (I) is less than 3 msec, tm=0.15ε -0.45 (I) Where tm is the mixing time, ε is the energy dissipation rate, Q is the flow rate, ΔP is the pressure loss, ρ is the density, V is the mixer volume, and ε = QΔP / ρV.

3. The production method according to claim 1 or 2, in, The total flow rate of the buffer solution and the flow rate of the solubilized solution of the insolubilized protein or the protein that has lost its higher order structure is 5 mL / min or more.

4. The production method according to claim 1 or 2, in, The total flow rate of the buffer solution and the flow rate of the solubilized solution of the insolubilized protein or the protein that has lost its higher order structure is 1650 mL / min or less.

5. The production method according to claim 1 or 2, in, The pressure loss before and after the micro mixer is 1 kPa to 10 MPa.

6. The manufacturing method according to claim 1 or 2, in, The flow rate X1 of the buffer solution is 10 to 1500 mL / min.

7. The manufacturing method according to claim 1 or 2, in, The inner diameter Y of the micro mixer is 0.1 to 1.0 mm.

8. The production method according to claim 1 or 2, in, In the refolding method, before the solubilization solution is passed through, the flow channel is filled with a solution containing no protein but a denaturing agent.

9. The production method according to claim 1 or 2, in, The refolded protein is a monomer.

10. The production method according to claim 1 or 2, in, The refolding step is followed by a purification step.

Citation Information

Patent Citations

  • Methods and systems for protein folding in vitro

    JP2009502173A

  • Method for refolding a protein

    US7651848B2

  • Method and system for in vitro protein folding

    CN101233152A